Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

AbbVie's 'Unjustified' Humira Settlements Divide Market, Class Action Claims

Mar 20 2019

• By Brenda Sandburg

Antitrust law - Image

Related Content

Biosimilar Vs. Biosimilar: Coherus Sues Amgen For Infringing Adalimumab Formulation Patents

Jan 26 2019

Biosimilar Patent Settlements: What Terms May Spur Antitrust Actions?

Oct 08 2018

Cipla, Piramal Launch Sensipar Generics Amid Growing Antitrust Challenges to Amgen/Teva Settlement

Mar 13 2019

From Pricing To Patents: Hearing Signals A Potential New Focus

Feb 27 2019

AbbVie Inks Sixth Humira Biosimilar Settlement, Battles Boehringer's 'Unclean Hands' Claim

Nov 09 2018

Does AbbVie Have 'Unclean Hands' From Building Humira Patent Thicket? Judge Allows Discovery

Jun 20 2018

AbbVie’s Downward Humira Guidance Worries Analysts

Jan 25 2019

Related Companies

AbbVie Inc.

Amgen, Inc.

Samsung Bioepis Co., Ltd.

Viatris Inc.

Novartis AG

Fresenius SE & Co. KGaA

Pfizer Inc.

Momenta Pharmaceuticals, Inc.

Coherus Oncology, Inc.

Teva Pharmaceutical Industries Ltd.

Boehringer Ingelheim GmbH

Johnson & Johnson

Allergan plc

Additional Topics

United States Biosimilars Legal Issues Policy Intellectual Property BioPharmaceutical

More from Biosimilars

More from Biosimilars & Generics

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window